ASH 2023 – Barbara Eichhorst
Barbara F. Eichhorst describes possible approaches to improve the early detection of molecular CLL relapses, discusses venetoclax-based first-line combinations in CLL, and rates the relative efficacy and safety of different BTK inhibitors in relapsed/refractory CLL while finally sharing her personal highlights from the ASH 2023 congress.
Here is the full ASH 2023 report.
More posts
Exploring chemotherapy-free approaches in the treatment of DLBCL
Exploring chemotherapy-free approaches in the treatment of DLBCL Smart Stop: qu
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies Treat
Follicular lymphoma: BTK inhibition and bispecific antibodies
Follicular lymphoma: BTK inhibition and bispecific antibodies Acalabrutinib in
Improving responses in multiple myeloma
Improving responses in multiple myeloma PERSEUS: D-VRd vs. VRd An established t
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Mantle cell lymphoma: emerging treatment regimens and new standards
Mantle cell lymphoma: emerging treatment regimens and new standards SYMPATICO:
